





IPO NOTE



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED



ISSUE OFFER Issue Opens on NOV 07, 2024 Issue Close on NOV 11, 2024 Total IPO size (cr) ₹2,200.00 Fresh issue (cr) ₹800.00 Offer For Sale (cr) ₹1,400.00 Price Band (INR) 70-74 Market Lot 200 Face Value (INR) ₹10 Listing At NSE, BSE Market Capitalization (cr) 13380.91

ISSUE BREAK-UP (%)	
QIB Portion	75%
NII Portion	15%
Retail Portion	10%

PROMOTER HOLDING %					
Pre Issue	Post Issue				
62.27%					

INDICATIVE TIMETABLE				
Basis of Allotment	12-11-2024			
Refunds/Unblocking ASBA Fund	13-11-2024			
Credit of Share to Demat A/c	13-11-2024			
Listing Date	14-11-2024			

Niva Bupa Health Insurance Company Limited is a joint venture between the Bupa Group and Fettle Tone LLP that provides insurance in the health sector.

OBJECTS OF THE ISSUE

- Augmentation of its capital base to strengthen solvency levels.
- General corporate purposes

FINANCIALS (RESTATED CONSOLIDATED)

PARTICULARS (IN CRORE)	FY 2024	FY 2023	FY 2022
Assets	6,191.87	3,876.57	2,738.44
Net Worth	2,049.59	831.12	507.65
AUM	5,458.23	3,366.0	2,401.3
Revenue	4,118.63	2,859.24	1,884.54
Net Profit/Loss of the year	81.85	12.54	-196.53

FINANCIAL RATIOS OF FY24



OUTLOOK & VALUATION

- A leading player in India's health insurance market.
- Among the fastest-growing companies in the sector.
- Posted a positive turnaround in FY23, though recent earnings in the first quarter of the current fiscal are in the negative.
- IPO pricing appears somewhat aggressive.
- Recommended only for high-risk investors considering an application.

॥ सर्वे भवन्तु धनिनः ॥





COMPANY PROFILE

- It had 14.99 million active lives insured as of June 30. 2024.
- The Company sell its products directly to customers through its direct sales channel.
- According to the Redseer Report, it has delivered strong customer service metrics on claims with a 91.93% claims settlement ratio for Fiscal 2024.
- It offer its customers the ability to access a comprehensive health ecosystem and service capabilities via its 'Niva Bupa Health' mobile application and website.
- According to the Redseer Report, it is one of India's largest and fastest growing SAHI based on overall health GDPI of ₹54,944.28 million in Fiscal 2024.



COMPETITIVE STRATEGIES

- Continuing to grow its product portfolio.
- Continue to invest in technology and analytics.
- Further expand its presence in existing geographies within India.
- Continue to invest in talent recruitment,
 development and retention to drive execution.
- Deepen culture of sustainability and "doing the right thing" to create a sustainable health franchise for future generations.



KEY CONCERNS

- Any failure to accurately estimate medical expenses or the frequency of claims could have a material adverse effect on its business.
- Significant portion of its business is generated from the health insurance line of business.
- Subject to extensive supervision and regulatory inspections.
- It has incurred losses in Fiscal 2022 and the three months ended June 30, 2024 and June 30, 2023.
- Operates in a highly competitive, evolving and rapidly changing industry.



KEY STRENGTHS

- Granular retail health insurer with a focus on delivering robust GWP growth, capital efficiency and profitability.
- Customer centric proposition driving customer experience and retention.
- Technology-led automated approach to customer servicing.
- Bupa parentage and brand associated with health insurance and healthcare.
- Domain Knowledge and Experience in Claims and Provider Management.
- Multi-Channel Diversified Pan-India Distribution.





COMPARISON WITH LISTED INDUSTRY PEERS

Name of the Company	EPS (Basic)	NAV	P/E	Net Profit (In CR.)	RoNW (%)
Niva Bupa Health Insurance Company Limited	0.51	12.06	153.7	81.8	5.68%
Peer Group					
Star Health and Allied Insurance Company Ltd	14.48	108.35	38.27	845	14.35%
ICICI Lombard General Insurance Company Ltd	39.03	242.75	48.91	1,918.59	17.17%
The New India Assurance Company Ltd	6.77	132.55	28.62	1,091.12	5.13%



DISCLAIMER:

The information contained herein are strictly confidential and are meant solely for the information of the recipient and shall not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written permission of Swastika Investment Ltd. ("SIL"). The contents of this document are for information purpose only. This document is not an investment advice and must not alone be taken as the basis for an investment decision. Before taking any decision to invest, the recipient of this document must read carefully the Red Herring Prospectus ("RHP") issued to know the details of IPO and various risks and uncertainties associated with the investment in the IPO of the Company. All recipients of this document must before acting on the given information/details, make their own investigation and apply independent judgment based on their specific investment objectives and financial position. They can also seek appropriate professional advice from their own legal and tax consultants, advisors, etc. to understand the risks and investment considerations arising from such investment. The investor should possess appropriate resources to analyze such investment and the suitability of such investment to such investor's particular circumstances before making any decisions on the investment. The Investor shall be solely responsible for any action taken based on this document. SIL shall not be liable for any direct or indirect losses arising from the use of the information contained in this document and accept no responsibility for statements made otherwise issued or any other source of information received by the investor and the investor would be doing so at his/her/its own risk. The information contained in this document should not be construed as forecast or promise or guarantee or assurance of any kind. The investors are not being offered any assurance or guaranteed or fixed returns on their investments. The users of this document mu

Swastika Investmart Ltd or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither Swastika Investmart Ltd nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Swastika Investment Ltd may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the Subject Company or third party in connection with the Research Report.

CORPORATE & ADMINISTRATIVE OFFICE - 48, Jaora Compound, M.Y.H. Road, Indore - 452 001 | Phone 0731 - 6644000

Compliance Officer: Ms. Sheetal Duraphe Email: compliance@swastika.co.inPhone: (0731) 6644 241

Swastika Investmart Limited, SEBI Reg. No.: NSE/BSE/MSEI: INZ000192732 Merchant Banking: INM000012102 Investment Adviser: INA000009843 MCX/NCDEX: INZ000072532 CDSL/NSDL: IN-DP-115-2015 RBI Reg. No.: B-03-00174 IRDA Reg. No.: 713.